We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
News

Multiplicom Appoints Board Chairman

Rectangle Image
News

Multiplicom Appoints Board Chairman

Read time:
 

Multiplicom NV has announced that Dr Ian Gilham has been appointed as Chairman of the Board of Directors.

"We are delighted that Ian has decided to join our team, strengthening the Board at this important time in the company’s development” said Dirk Pollet CEO of Multiplicom.

Pollet continued, “Ian has worked with many companies providing them with valuable experience in research, development and the commercialization of products. We look forward to working with him and have every confidence that his expertise will help us grow the company and deliver value for both new and existing investors.”

Dr. Gilham was Chief Executive Officer of Axis-Shield plc, a public in-vitro diagnostics company, until Alere acquired it in November 2011.

Whilst at Axis-Shield, Dr. Gilham held the position of Chief Operating Officer and became Chief Executive Officer in January 2008.

Before joining Axis-Shield, Dr. Gilham was VP Pharmacogenetics at GSK where he was responsible for the delivery of pharmacogenetic tests, as well as novel diagnostic tests used in targeting GSK’s medicines.

Prior to joining GSK, Dr. Gilham held international general management, marketing, business development and R&D positions with Abbott Laboratories, Celltech and Amersham, gaining wide expertise in the fields of clinical diagnostics and pharmaceuticals.

Commenting on his appointment, Dr Ian Gilham said: “It is with great pleasure that I have accepted the opportunity to become Chairman to the Board of Multiplicom. The molecular diagnostics market is undergoing rapid growth, fuelled by the decreasing cost of DNA sequencing and increased availability of genetic information that links genes to health and disease. The outlook is very promising for the genomic and somatic mutations that Multiplicom is focused on. I look forward to working with the Board to make sure the company fulfills its clearly evident potential.”

Advertisement